ADP-Ribosylation factor 6 regulates tumorigenic and invasive properties in vivo

Vandhana Muralidharan-Chari, Holly Hoover, James Clancy, Jill Schweitzer, Mark A. Suckow, Valerie Schroeder, Francis J. Castellino, Jeffrey S. Schorey, Crislyn D'Souza-Schorey

Research output: Contribution to journalArticlepeer-review

83 Scopus citations


This study shows that the small GTP-binding protein ADP- ribosylation factor 6 (AKF6) is an important regulator of tumor growth and metastasis. Using spontaneous melanoma tumor growth assays and experimental metastasis assays in nude mice, we show that sustained activation of ARF6 reduces tumor mass growth but significantly enhances the invasive capacity of tumor cells. In contrast, mice injected with tumor cells expressing a dominantly inhibitory ARF6 mutant exhibited a lower incidence and degree of invasion and lung metastasis compared with control animals. Effects on tumor growth correlate with reduced cell proliferation capacity and are linked at least in part to alterations in mitotic progression induced by defective ARF6 cycling. Furthermore, phospho- ERK levels in subcultured cells from ARF6(GTP) and ARF6(GDP) tumor explants correlate with invasive capacity. ARF6-induced extracellular signal-regulated kinase (ERK) signaling leads to Racl activation to promote invadopodia formation and cell invasion. These findings document an intricate role for ARF6 and the regulation of ERK activation in orchestrating mechanisms underlying melanoma growth, invasion, and metastases.

Original languageEnglish
Pages (from-to)2201-2209
Number of pages9
JournalCancer Research
Issue number6
StatePublished - Mar 15 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'ADP-Ribosylation factor 6 regulates tumorigenic and invasive properties in vivo'. Together they form a unique fingerprint.

Cite this